Diagnostic significance of clinical and laboratory indices in predicting non-alcoholic fatty liver disease during screening studies

Cover Page

Cite item

Full Text

Abstract

Aim. To study the significance of clinical and laboratory non-invasive indexes along with the insulin resistance index when carrying out diagnostic assessment of non-alcoholic fatty liver disease (NAFLD) during screening examinations.

Materials and methods. The study involved 348 employees working at oil-production enterprises. An ultrasound scanning of the liver was carried out to assess the criteria of NAFLD. The following indexes were calculated: fatty liver index (FLI), hepatic steatosis index (HSI), lipid accumulation products (LAP), and homeostasis model assessment of insulin resistance (HOMA1-IR). The prognostic significance of these indexes in relation to the probability of NAFLD diagnosis based on ultrasound data was studied using single-factor and multi-factor logistic regression models followed by ROC-analysis.

Results. The FLI, HSI, and HOMA1-IR indexes in single-factor logistic regression models showed a high statistical significance when carrying out diagnostic assessment the NAFLD with good model calibration capability. The percentage of correct binary classification regards the presence/absence of NAFLD amounted to 82.4% for FLI, 79.7% for HSI, and 72.7% for HOMA1-IR (p<0.001). According to the ROC-analysis, the area under the curve (AUC) by the NAFLD diagnostic assessment was 0.917 (95% CI 0.889–0.945); 0.880 (95% CI 0.846–0.915) and 0.849 (95% CI 0.764–0.934), respectively. The multi-factor logistic regression model with the inclusion of FLI and HOMA1-IR 72.7% enabled us to achieve the correct binary classification in terms of NAFLD in 84.2% of cases. When it comes to the ROC-analysis, considering the probabilities predicted in the multi-factor logistic model as the test variable and NAFLD in ultrasound examination as the state variable, it was possible to set the value of AUC 0.933 (95% CI 0.882–0.985).

Conclusion. The studied clinical and laboratory indexes (FLI, HSI, HOMA1-IR) have a high diagnostic significance regarding NAFLD diagnosed using ultrasonographic criteria. The application of the proposed two-factor logistics model makes it possible to predict the presence of NAFLD when examining a large number of patients, without involving additional ultrasound diagnostics specialists in order to use medical resources rationally.

About the authors

Aleksandr E. Nosov

Federal Scientific Center for Medical and Preventive Health Risk Management Technologies

Author for correspondence.
Email: nosov@fcrisk.ru
ORCID iD: 0000-0003-0539-569X

кандидат медицинских наук, заведующий стационаром (отделение профпатологии терапевтического профиля)

Russian Federation, Perm

Mariia T. Zenina

Federal Scientific Center for Medical and Preventive Health Risk Management Technologies

Email: nosov@fcrisk.ru
ORCID iD: 0000-0001-6623-3075

врач ультразвуковой диагностики

Russian Federation, Perm

Olga Y. Gorbushina

Federal Scientific Center for Medical and Preventive Health Risk Management Technologies

Email: nosov@fcrisk.ru
ORCID iD: 0000-0002-7592-3219

врач-терапевт стационара (отделение профпатологии терапевтического профиля)

Russian Federation, Perm

Anastasiia S. Baidina

Federal Scientific Center for Medical and Preventive Health Risk Management Technologies

Email: nosov@fcrisk.ru
ORCID iD: 0000-0003-3131-5868

кандидат медицинских наук, врач-кардиолог консультативно-поликлинического отделения

Russian Federation, Perm

Elena M. Vlasova

Federal Scientific Center for Medical and Preventive Health Risk Management Technologies

Email: nosov@fcrisk.ru
ORCID iD: 0000-0003-3344-3361

кандидат медицинских наук, заведующий центром профессиональной патологии

Russian Federation, Perm

Vadim B. Alekseev

Federal Scientific Center for Medical and Preventive Health Risk Management Technologies

Email: nosov@fcrisk.ru

доктор медицинских наук, директор

Russian Federation, Perm

References

  1. Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019;95(1124):314-22. doi: 10.1136/postgradmedj-2018-136316
  2. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obesity Facts. 2016;9(2):65-90. doi: 10.1159/000443344
  3. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clinical Gastroenterol Hepatol. 2015;13:643-54. doi: 10.1016/j.cgh.2014.04.014
  4. Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600. doi: 10.1016/j.jhep.2016.05.013
  5. Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(1):47-64. doi: 10.1016/j.jhep.2014.12.012
  6. Mantovani A, Zaza G, Byrne CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2018;79:64-76. doi: 10.1016/j.metabol.2017.11.003
  7. Оганов Р.Г., Симаненков В.И., Бакулин И.Г., и др. Коморбидная патология в клинической практике. Кардиоваскулярная терапия и профилактика. 2019;18(1):5-66 [Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;(1):5-66 (in Russian)]. doi: 10.15829/1728-8800-2019-1-5-66
  8. Практическое руководство по ультразвуковой диагностике. Общая ультразвуковая диагностика. Под ред. В.В. Митькова. М.: Видар-М, 2005 [A practical guide to ultrasound diagnostics. General ultrasound diagnostics. Ed. VV Mitkov. Moscow: Vidar-M, 2005 (in Russian)].
  9. Li X, Zhou Z, Qi H, et al. Replacement of insulin by fasting C-peptide in modified homeostasis model assessment to evaluate insulin resistance and islet beta cell function. Journal of Central South University. Medical sciences. 2004;29(4):419-23
  10. Basukala P, Jha B, Yadav BK, Shrestha PK. Determination of Insulin Resistance and Beta-Cell Function Using Homeostatic Model Assessment in Type 2 Diabetic Patients at Diagnosis. Diabetes Metab J. 2018;9(3):790. doi: 10.4172/2155-6156.1000790
  11. Валеева В.Ф., Нуруллина Г.И. Диагностическая ценность С-пептида и модифицированных индексов HOMA при различных нарушениях углеводного обмена на фоне терапии глюкокортикоидами. Мед. вестн. юга России. 2018;9(1):23-31 [Valeeva FV, Nurullina GI. C-peptide and modified HOMA-index in different carbohydrate metabolism disturbances during glucocorticoid therapy. Medical Herald of the South of Russia. 2018;9(1):23-31 (in Russian)]. doi: 10.21886/2219-8075-2018-9-1-23-31
  12. Nurullina G. The role of HOMA-IR and HOMA_ISLET indices in different carbohydrate metabolism disorders during glucocorticoid therapy. Ann Rheum Dis. 2017;76:1161. doi: 10.1136/annrheumdis-2017-eular.5721
  13. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-95. doi: 10.1002/hep.20466
  14. Prati D, Taioli E, Zanella A, et al. Updated deinitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1-10. doi: 10.7326/0003-4819-137-1-200207020-00006
  15. Ballestri S, Nascimbeni F, Baldelli E, et al. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism. 2017;72:57-65. doi: 10.1016/j.metabol.2017.04.003
  16. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6(33). doi: 10.1186/1471-230X-6-33
  17. Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol. 2010;10(98). doi: 10.1186/1471-230X-10-98
  18. Xia C, Li R, Zhang S, et al. Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. Eur J Clin Nutr. 2012;66(9):1035-8. doi: 10.1038/ejcn.2012.83
  19. Zhu J, He M, Zhang Y, et al. Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study. Endocr J. 2018;65(3):373-81. doi: 10.1507/endocrj.EJ17-0466
  20. Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42:503-8. doi: 10.1016/j.dld.2009.08.002
  21. Cuthbertson DJ, Weickert MO, Lythgoe D, et al. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol. 2014;171(5):561-9. doi: 10.1530/EJE-14-0112
  22. Huang X, Xu M, Chen Y, et al. Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese. Medicine. 2015;94(40):e1682. doi: 10.1097/MD.0000000000001682
  23. Yang BL, Wu WC, Fang KC, et al. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS One. 2015;10(3):e0120443. doi: 10.1371/journal.pone.0120443.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. ROC-curves for FLI, HSI, LAP and NAFLD indices according to ultrasound data.

Download (75KB)
3. Fig. 2. ROC-curves for the HOMA1-IR index and NAFLD according to ultrasound data.

Download (64KB)
4. Fig. 3. ROC-curves for predicted probability based on multivariate logistic model and NAFLD from ultrasound data.

Download (63KB)

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies